Pharma Focus America

Novartis Canada and Clarius Mobile Health Collaborate to Enhance Psoriatic Arthritis Treatment Norms

Tuesday, May 28, 2024

Novartis Pharmaceuticals Canada Inc. is excited to announce a collaboration with Clarius Mobile Health (Clarius) to support early detection of psoriatic arthritis in Canada. By enhancing access to ultrasound technology, rheumatologists will be better equipped to identify diagnostic markers sooner, potentially shortening the time to diagnosis for PsA patients.

Novartis Canada, expressed enthusiasm about the partnership, stating, “At Novartis, we recognize the enormous potential AI holds for our industry and the broader healthcare landscape. Our collaboration with Clarius has the capacity to revolutionize PsA detection, with the potential to expand to other Immunology indications, transcending specialties and reaching beyond Canada.”

Novartis and Clarius both share a dedication to improving accessibility to medical imaging in Canada. This partnership aims to provide rheumatologists with handheld ultrasound devices and comprehensive training, support, and education through various events, including in-person, virtual, and asynchronous sessions. As part of the agreement, Novartis will gather evidence to assess and track adoption, usage, and impact, evaluating how ultrasound utilization in routine practice correlates with early detection of PsA.

Dr. Mohammad Bardi, Clinical Instructor at the University of British Columbia and Staff Rheumatologist at Vancouver General Hospital, emphasized the significance of point-of-care ultrasound in enhancing patient care, stating, “The use of handheld ultrasound empowers us as rheumatologists to enhance patient education, adherence, and therapeutic confidence, particularly in settings where access to traditional ultrasound systems is limited.”

Clarius, a leader in the medical device industry, has pioneered the miniaturization of ultrasound technology to improve medical imaging accessibility. Their third-generation Clarius HD3, approved by Health Canada in 2022, offers a range of high-performance handheld ultrasound scanners that seamlessly connect to clinicians' Apple and Android smart devices via an AI-powered application. The Clarius app utilizes advanced artificial intelligence to instantly display optimized images in real-time, enabling clinicians to make informed decisions at the point of care without the need for patient referrals to imaging centers.

Clarius, expressed excitement about Novartis' commitment to improving care for PsA patients, saying, “We are inspired by Novartis' mission and their innovative approach to accelerating diagnosis with real-time ultrasound imaging. This partnership between a pharmaceutical and a medical technology company has the potential to significantly improve patient outcomes and alleviate the burden on our healthcare system.”

 

Source: novartis.com

Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024